相关实验视频

Updated: Jul 20, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

基于心血管疾病纳米颗粒的微RNA输送

Nan Wang¹, Chunyan Chen¹, Jianmin Ren¹

¹Department of Pharmacy, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Haishu District, Ningbo, 315010, Zhejiang, China.

Molecular and cellular biochemistry

|August 5, 2023

概括

微RNA (miRNA) 对治疗心血管疾病,如心肌梗塞等有前途. 纳米输送系统为心肌病提供有针对性的治疗,并减少心肌病的副作用.

科学领域:

生物医学工程生物医学工程
分子生物学分子生物学
心脏病学心脏病学

背景情况:

心血管疾病,特别是心肌梗塞,对健康构成重大风险.
目前用于心血管疾病的治疗方法往往缺乏选择性,限制了治疗疗效.
微RNAs (miRNAs) 在心血管疾病的发病过程中起着至关重要的作用.

研究的目的:

审查基于miRNA治疗心血管疾病的最新进展.
探索使用miRNA用于心肌病治疗的潜力和挑战.
讨论纳米输送系统用于miRNA治疗的应用.

主要方法:

关于miRNA和心血管疾病的当前文献的综述.
分析不同的纳米载体类型 (无机,聚合物,脂质体) 用于miRNA输送.
对心肌病治疗miRNA纳米药物开发的研究摘要.

主要成果:

基于miRNA的疗法显示出治疗心血管疾病的潜力.
纳米传递系统可以增强miRNA的向性并减少副作用.
各种纳米载体正在研究有效的miRNA封装.

结论:

miRNA纳米药物代表了对心肌病的有前途的新治疗策略.
纳米技术可以改善基于miRNA的心血管治疗的治疗结果.
需要进一步的研究来克服miRNA传递和应用方面的挑战.

关键词:

心血管疾病是什么心血管疾病运营商运营商运营商这是一个微型RNA.纳米颗粒纳米颗粒

更多相关视频

Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo

Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo

Published on: February 5, 2019

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...